Structure-guided development of G protein-biased apelin receptor agonists for cardiovascular disease
Journal of Zhejiang University-SCIENCE B · 2026-10 · 27 (10) · 1059-1065
DOI: 10.1631/jzus.b2600160 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Zhejiang University-SCIENCE B, online erschienen am 30.10.2026. Verfasst von Weiwei Wang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Department of Pharmacology of Sir Run Run Shaw Hospital, MOE Frontier Science Center for Brain Research and Brain-Machine…. Hauptthemen laut MEDLINE: Apelin Receptors, Cardiovascular Diseases, GTP-Binding Proteins. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: the National Natural Science Foundation of China.
Abstract (Originalsprache)
Apelin receptor (APLNR) is a crucial G protein-coupled receptor that plays a central role in cardiovascular homeostasis; therefore, it represents a promising therapeutic target for heart failure, myocardial infarction, cardiac hypertrophy, and pulmonary arterial hypertension. However, the activation of APLNR simultaneously engages inhibitory G protein (Gi)-mediated protective signaling and β-arrestin pathways that are associated with pathological cardiac remodeling, thereby imposing significant limitations and challenges for the therapeutic development of conventional balanced agonists. Recent advances in structural biology and pharmacology have provided valuable mechanistic insights into receptor activation and biased signaling. High-resolution cryo-electron microscopy (cryo-EM) structures revealed the conformational basis of signal bias, enabling the rational design of fully G protein-biased agonists that retain cardiovascular benefits while avoiding hypertrophic effects. This review summarizes recent progress in APLNR signaling mechanisms and biased ligand development, highlighting a number of emerging strategies for the precision pharmacological targeting of this receptor. Apelin受体(APLNR)是一种重要的G蛋白偶联受体,在维持心血管稳态中发挥关键作用,是心力衰竭、心肌梗死、心肌肥厚和肺动脉高压等心血管疾病的潜在治疗靶点。然而,APLNR激活后既可启动具有心血管保护作用的抑制型G蛋白(Gi)介导信号通路,也可激活与病理性心脏重构相关的β-arrestin信号通路。这种复杂的信号转导特征给传统平衡型激动剂的临床转化带来了显著挑战。近年来,结构生物学与药理学的快速发展为阐明APLNR的受体激活机制和偏向性信号转导提供了重要的结构与理论基础。高分辨率冷冻电镜结构进一步揭示了APLNR信号偏向性的构象基础,为合理设计选择性激活G蛋白信号通路的偏向性激动剂提供了可能。这类激动剂有望在保留心血管保护作用的同时,避免由β-arrestin信号通路介导的心肌肥厚效应。本文综述APLNR信号转导机制及偏向性配体研发的最新进展,并重点讨论精准靶向APLNR的潜在药物设计策略及其在心血管疾病治疗中的应用前景。.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology and Department of Pharmacology of Sir Run Run Shaw Hospital, MOE Frontier Science Center for Brain Research and Brain-Machine Integration, and Liangzhu Laboratory, Zhejiang University School of M…
- Department of Cardiology of Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou 310016, China.
Förderung
- the National Natural Science Foundation of China
Zitieren
APA
Wang, W., Zhang, J., Zhang, J., Yang, Y., & Zhang, Y. (2026). Structure-guided development of G protein-biased apelin receptor agonists for cardiovascular disease. Journal of Zhejiang University-SCIENCE B, 27(10), 1059-1065. https://doi.org/10.1631/jzus.b2600160
Vancouver
Wang W, Zhang J, Zhang J, Yang Y, Zhang Y. Structure-guided development of G protein-biased apelin receptor agonists for cardiovascular disease. Journal of Zhejiang University-SCIENCE B. 2026;27(10):1059-1065. doi:10.1631/jzus.b2600160
BibTeX
@article{Wang2026,
author = {Wang, Weiwei and Zhang, Jiangrong and Zhang, Jiahua and Yang, Yixin and Zhang, Yan},
title = {Structure-guided development of G protein-biased apelin receptor agonists for cardiovascular disease},
journal = {Journal of Zhejiang University-SCIENCE B},
year = {2026},
volume = {27},
number = {10},
pages = {1059--1065},
doi = {10.1631/jzus.b2600160}
}
EUVIMED